---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030136"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:24:55.617359+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share

## Summary
- Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.
- IMCIVREE received FDA approval for acquired hypothalamic obesity on Mar 19; >150 patient start forms in first six weeks.
- European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026.
- Net loss $(56.7)M ($(0.83)/share) vs $(50.8)M ($(0.81)/share) in Q1 2025; cash $340.6M.
- Phase 3 EMANATE trial missed primary endpoint; positive post-hoc signals in SRC1 and POMC insufficiencies.

## SEC filing metadata
- accession: 0001628280-26-030136
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/0001628280-26-030136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/rytm-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030136
- JSON: https://secwatch.observer/filing/0001628280-26-030136.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030136.txt

## Source-grounded claims
- claim_id: eba1a1a1d21e2044890782fa5ebf47b4ab73f093
  claim: RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2026 results: revenue $60.1 million.
  evidence_excerpt: Revenue from global sales of IMCIVREE was $60.1 million for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/0001628280-26-030136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.